Clinical Trial Update: A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity [Phase 2]

View source ↗

Summary

Phase 2 dose-range study evaluating alniglipron (GSBR-1290) in adults with obesity or overweight and weight-related comorbidities; the trial is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Aleniglipron (GSBR-1290)

Snippet

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Conditions: Obesity, Overweight | Phase 2 | Status: ACTIVE_NOT_RECRUITING